MedTrace Logo

Efficacy of Treating First Episode Psychosis With Folic Acid,B12 and B6 in Addition to Antipsychotic Medication

NCT00202280 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2015-11-20

No results posted yet for this study

Summary

The purpose of this study is to determine whether Vitamin B12,B6 and Folic Acid are effective with antipsychotic medication in the treatment of First Episode Psychosis.The B-complex Vitamins' homocysteine lowering properties may have an effect on cognition and symptoms. We are examining changes in symptoms and cognition over a 3 month period.

Conditions

  • First Episode Psychosis

Interventions

DRUG

Folic Acid 5mg, Vitamin B12 0.4mg and B6 50mg

Sponsors & Collaborators

  • Stanley Medical Research Institute

    collaborator OTHER

  • Melbourne Health

    lead OTHER

Principal Investigators

  • Dr Colin P O'Donnell, MB,MRCPsych · ORYGEN Research Centre , ORYGEN Youth Health,Department of Psychiatry, University of Melbourne

  • Prof Patrick D McGorry, PhD FRANZP · ORYGEN Research Centre , ORYGEN Youth Health,Department of Psychiatry, University of Melbourne

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
15 Years
Max Age
25 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-09-30
Primary Completion
2006-09-30
Completion
2009-06-30

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00202280 on ClinicalTrials.gov